🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, Lynparza 100 mg film-coated tablets, Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Imfinzi 50 mg/ml, Lynparza 100 mg, Lynparza 150 mg, Myfenax 250 mg hard capsules, Flixabi 100 mg p

    AstraZeneca AB

    Endometrial Cancer

    phase 3 small molecule active

    1 trial

  2. N-Acetyl-L-Leucine, granules for suspension

    Intrabio Ireland Limited

    CACNA1A Disorders

    phase 3 small molecule active

    1 trial

  3. N-Acetylcysteine

    The First People's Hospital of Lianyungang

    Thrombotic Microangiopathies

    phase 3 small molecule completed

    1 trial

  4. N-Acetylcysteine

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 3 small molecule completed

    2 trials

  5. N-Acetylcysteine (NAC) Treatment

    The First People's Hospital of Lianyungang

    Thrombotic Microangiopathy

    phase 3 small molecule active

    1 trial

  6. N-acetylgalactosamine 4-sulfatase

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis VI

    phase 3 small molecule completed

    3 trials

  7. NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    5 trials

  8. NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  9. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  10. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  11. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  12. NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    5 trials

  13. NBI-1117568, NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia, Schizophrenia

    phase 3 small molecule active

    1 trial

  14. NBI-1117568, NBI-1117568, NBI-1117568 Placebo Capsule

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  15. NBI-34060

    NEUROCRINE BIOSCIENCES INC

    Insomnia

    phase 3 small molecule terminated

    1 trial

  16. NBI-74788, Crinecerfont placebo for oral capsules

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  17. NBI-98854

    NEUROCRINE BIOSCIENCES INC

    Tardive Dyskinesia

    phase 3 small molecule completed

    6 trials

  18. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA THERAPEUTICS, INC.

    Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)

    phase 3 small molecule terminated

    1 trial

  19. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA THERAPEUTICS, INC.

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 3 small molecule active

    2 trials

  20. NE-58095 IR

    Takeda

    Involutional Osteoporosis

    phase 3 small molecule completed

    1 trial

  21. NEORAL® Soft Gelatin Capsules 100mg, Methotrexate 2.5 mg Tablets, Zilbrysq 16.6 mg solution for injection in pre-filled syringe, Prednisolone 5mg Tablets, Azathioprine Tablets 50mg Oprisine, Privigen 100 mg/ml solution for infusion, Soliris 300 mg concentrate for solution for infusion, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 50mg, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 10mg, Methotrexate 2.5 mg Tablets, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 25mg, K

    Kyverna Therapeutics

    Generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  22. NFC-1

    Avalo Therapeutics

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  23. NI-501; emapalumab, NI-501; emapalumab

    Swedish Orphan Biovitrum Pty Ltd

    Macrophage activation syndrome (MAS) in the context of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult onset Still's disease (AOSD). MAS in the context of pediatric and adult Systemic Lupus Erythematosus (SLE).

    phase 3 small molecule active

    1 trial

  24. NICOPASS 1,5 mg SANS SUCRE MENTHE FRAICHEUR, pastille édulcorée à l'aspartam et à l’acésulfame potassique, V0018 Placebo

    Pierre Fabre Medicament

    Cessation of smoking

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources